ANI Pharmaceuticals

ANIP · NASDAQ🇺🇸

Overview

Earnings Dividends Seasonality Metrics

NOV

7

Q3 2025

Reported

Reported earnings 3 months ago

Cortrophin Gel Revenue Growth

93.8%

0

Generics Revenue Growth

Previous year: $69.5M

Previous year: $1.29B

+9.4%

ANI Pharmaceuticals

Unlock previous datapoints

Upgrade

ANI Pharmaceuticals

Unlock previous datapoints

Upgrade

ANI Pharmaceuticals Revenue by Segment

Revenue by Segment

Cortrophin Gel Revenue

CapyFin.com

ILUVIEN and YUTIQ Revenue

CapyFin.com

Rare Disease Total Revenue

CapyFin.com

Brands Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Generic Pharmaceutical Products Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Royalties and Other Revenue

CapyFin.com

Generics and Other Total Revenue

CapyFin.com

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Products

Get in Touch

Resources

ANI Pharmaceuticals

ANI Pharmaceuticals

ANI Pharmaceuticals

ANI Pharmaceuticals Revenue by Segment

Revenue by Segment

Cortrophin Gel Revenue

ILUVIEN and YUTIQ Revenue

Rare Disease Total Revenue

Brands Revenue

Generic Pharmaceutical Products Revenue

Royalties and Other Revenue

Generics and Other Total Revenue

Revenue & Expenses

Historical Earnings Impact

Avg. Return Before/After Earnings